Update shared on03 Sep 2025
Fair value Increased 2.70%The modest upward revision in Glenmark Pharmaceuticals' consensus price target to ₹2246 appears primarily driven by a slightly higher future P/E multiple, with revenue growth forecasts largely unchanged.
What's in the News
- Glenmark announced the upcoming US launch of Micafungin for Injection, entering a $60.7 million annual market with a bioequivalent product to Astellas Pharma's Mycamine.
- A Board Meeting is scheduled to consider and approve unaudited financial results for the first quarter ended June 30, 2025.
- A Special Shareholders Meeting was convened to consider appointing Mr. Anurag Mantri as Executive Director and Global Chief Financial Officer via postal ballot.
- AcuCort AB signed a Letter of Intent with Glenmark for the distribution and marketing of Zeqmelit in six European countries, with a definitive agreement expected in 2025.
- Glenmark launched TEVIMBRA (tislelizumab) and announced the upcoming launch of BRUKINSA (zanubrutinib) in India, marking significant entries into immune-oncology and B-cell malignancy treatment segments.
Valuation Changes
Summary of Valuation Changes for Glenmark Pharmaceuticals
- The Consensus Analyst Price Target has risen slightly from ₹2187 to ₹2246.
- The Future P/E for Glenmark Pharmaceuticals has risen slightly from 35.28x to 36.25x.
- The Consensus Revenue Growth forecasts for Glenmark Pharmaceuticals remained effectively unchanged, at 12.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.